Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
151 results about "Arginase" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Arginase (EC 3.5.3.1, arginine amidinase, canavanase, L-arginase, arginine transamidinase) is a manganese-containing enzyme. The reaction catalyzed by this enzyme is: arginine + H₂O → ornithine + urea. It is the final enzyme of the urea cycle. It is ubiquitous to all domains of life.
sgRNA for promoting development of cotton lateral root and application thereof
ActiveCN107043775AImprove stress resistancePromote absorptionHydrolasesNucleic acid vectorFiberAgricultural science
The invention discloses sgRNA for promoting development of cotton lateral root, a target sequence of sgRNA is respectively composed of the nucleotide sequences shown in SEQ ID No.1 or SEQ ID No.2, and two target sequences can be used by combination. The expression of cotton argininase gene can be inhibited through a CRISPR / Cas9 gene editing system. Compared with wild type plants, the lateral root number of the gene editing plants obtained by silencing the cotton argininase gene is obviously increased, the root surface area is obviously increased, No content is increased, absorption and utilization of nitrogen element and other nutrients by cotton are increased, and sgRNA has important meaning for increasing the cotton fiber output and quality as well as increasing the cotton stress resistance.
Owner:THE INST OF BIOTECHNOLOGY OF THE CHINESE ACAD OF AGRI SCI
Treatment and diagnosis of conditions associated with elevated arginase activity
ActiveUS20050158401A1Reduce the amount requiredLess-expensive therapyBiocidePeptide/protein ingredientsNitric oxideBioavailability
The invention features methods and compositions for diagnosis and treatment of conditions associated with decreased nitric oxide bioavailability, such as a condition associated with elevated arginase activity, using an arginine- and / or arginase-inhibitor based therapy, which therapies include administration of arginine or an arginase inhibitor, either alone or in combination. The invention also contemplates administration of magnesium with arginine, an arginase inhibitor, or with arginine-arginase inhibitor combination therapy. The invention also features methods and compositions for diagnosis, including prognosis, of conditions associated with arginase activity by assessing the ratio of arginine to ornithine in samples from a subject.
Owner:CHILDREN S HOSPITAL &RES CENT AT OAKLAN
Inhibition of colony stimulating factor-1 receptor signaling for the treatment of brain cancer
InactiveUS20150119267A1Compound screeningApoptosis detectionAfter treatmentColony-stimulating factor
The present invention provides a method of screening brain tumor patients for treatment with inhibitor of CSF-1R, based on differential gene expression including adrenomeduUin (ADM), arginase 1 (ARG1), clotting factor F13A1, mannose receptor C type 1 (MRC1 / CD206), and protease inhibitor SERPINB2 after treatment with the inhibitor. Based on the same differential gene expression profile, the present invention also provides a method of screening a compound to treat brain cancer.
Owner:SLOAN KETTERING INST FOR CANCER RES
Synergistic drug compound for treating tumor and preparation method thereof
InactiveCN105879030AGood treatment effectHigh activityPeptide/protein ingredientsAntineoplastic agentsMelanomaTherapeutic effect
The invention belongs to the field of medicine and biotechnology, and relates to a synergistic drug compound for treating tumors and a preparation method thereof. The drug compound is composed of one or more cell autophagy inhibitors and arginase, especially human recombinant Arginase is made into a synergistic drug compound for treating tumors, and the synergistic drug compound can inhibit autophagy by inhibiting autophagy through autophagy inhibitors to increase tumor cells' ability to arginase. sensitivity, and enhance the therapeutic effect of arginase, especially human recombinant arginase, on tumors, especially triple-negative breast cancer cells. The drug compound of the present invention can be used for clinical treatment of breast cancer, melanoma, lung cancer, brain tumor, lymphoma, leukemia and myeloma.
Owner:FUDAN UNIV
Arginase inhibitors and methods of use thereof
ActiveUS8894970B2Compounds screening/testingUltrasonic/sonic/infrasonic diagnosticsNitric oxideArginase
Owner:ASTRAZENECA AB
Compositions and methods for inhibiting arginase activity
ActiveUS10065974B2Improve throughputLimit deliveryBoron compound active ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsArginaseMedicinal chemistry
Owner:PRECISION PHARM INC
Compositions and Methods for Inhibiting Arginase Activity
ActiveUS20160375044A1Improve the level ofBiocideBoron compound active ingredientsCancer therapyArginase
Owner:CALITHERA BIOSCIENCES INC
Compositions and methods for inhibiting arginase activity
ActiveUS10287303B2Boron compound active ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsMedicineArginase
Owner:PRECISION PHARM INC
Compositions of engineered human arginases and methods for treating cancer
Compositions and methods for the treatment of cancer are described, and, more preferably, to the treatment of cancers that do not express, or are otherwise deficient in, argininosuccinate synthetase, with enzymes that deplete L-Arginine in serum. In one embodiment, the present invention contemplates an arginase protein, such as a human Arginase I protein, comprising at least one amino acid substitution and a metal cofactor, said protein comprising an increased catalytic activity when compared with a native human Arginase I.
Owner:AERASE
Method for preparing d-arginine hydrochloride and l-ornithine hydrochloride by splitting dl-arginine by microbial enzymatic method
InactiveCN102286602AIncrease enzyme activityIncrease vitalityMicroorganism based processesFermentationEscherichia coliD-Arginine
A method for preparing D-arginine hydrochloride and L-ornithine hydrochloride by splitting DL-arginine by microbial enzymatic method. The present invention utilizes the fermented bacterium of recombinant E. coli or its spray-dried preparation that highly expresses L-arginase as an enzyme source, uses DL-arginine as a substrate, and splits DL-arginine through an enzymatic reaction to produce D-arginine and L-ornithine. The resulting liquid is converted into L-ornithine monohydrochloride by adding hydrochloric acid, then adding a certain volume of ethanol to precipitate it, and collecting the precipitate to obtain L-ornithine hydrochloride; in the supernatant, D- The purification method of arginine is: adsorption and elution of ion exchange resin, concentration and drying under reduced pressure, to obtain D-arginine hydrochloride; this patent provides a new D-arginine hydrochloride and L- Green production process route of ornithine hydrochloride.
Owner:天津启仁医药科技有限公司
Pharmaceutical preparation and method of treatment of human malignancies with arginine deprivation
ActiveUS20050244398A1Improve enzymatic activityImprove stabilityBacteriaHydrolasesMalignancyArginase
The present invention provides an isolated and substantially purified recombinant human arginase having sufficiently high enzymatic activity and stability to maintain Adequate Arginine Depletion in a patient. The present invention also provides a pharmaceutical composition comprising the modified invention enzyme and method for treatment of diseases using the pharmaceutical composition.
Owner:BIO CANCER TREATMENT INT
Double-stained kit for auxiliary diagnosis of benign or malignant hepatocellular tumor and application thereof
InactiveCN104730242AIncrease the amount of informationImprove differential stainingMaterial analysisInformation quantityDifferential diagnosis
The invention discloses a double-stained kit for auxiliary diagnosis of benign or malignant hepatocellular tumor and application thereof. The kit comprises the following components: mixed primary antibody of Arginase-1 and Glypian-3, mixed second antibody of alkaline phosphatase conjugated goat anti-rabbit second antibody and horse radish peroxidase labeled goat anti -mouse second antibody, chromogenic reagent AP-Red and DAB (Diaminobenzidine), and TBS (Tris buffer saline) buffer solution. Two immunohistochemical labels provided by the invention are used for auxiliary diagnosis of benign or malignant hepatocellular tumor and differentiation degrees of tumor, the two labels are displayed through staining label by different detection systems and utilizing the differences of target cells stained by each label, information quantity and differential staining on the same radiograph are improved, readability and accuracy of radiograph reading are increased, so that the double-stained kit has important significance to identification of benign or malignant hepatocellular tumor and differentiation degrees of tumor.
Owner:GUANGZHOU LBP MEDICINE SCI & TECH
Method for preparing L-ornithine-L-aspartate salt
InactiveCN102102118AHigh purityIncrease productionOn/in organic carrierFermentationOrnithine aspartateL-ornithine L-aspartate
The invention relates to a method for preparing L-ornithine-L-aspartate salt. The L-ornithine-L-aspartate salt is produced through conversion of arginase. The method comprises the following process steps of: (1) preparing immobilized enzyme; (2) optimizing conversion conditions; and (3) extracting product and refining. Compared with the prior art, the method has the advantages that: production cost is low, the production conditions are mild, impurities in a conversion system are a few, the process steps are simple, the production operation is safe, the purity is high, 300 to 320g of L-ornithine-L-aspartate salt is contained in each liter of reaction solution, the yield is high, the conversion rate of arginase is over 95 percent and the like.
Owner:湖南天成生化科技有限公司
Sulfhydryl modified recombinant human arginase I, as well as preparation method and application thereof
The invention relates to a sulfhydryl modified recombinant human arginase I, as well as preparation method and application thereof. The arginase is a recombinant human arginase I obtained by recombinant technology and protein purification technology; the used polyethylene glycol is a Y-type polyethylene glycol maleimide which is a branched PEG (polyethylene glycol) derivative containing two methoxy groups, the molecular weight is 40Kd, and the active end group maleimide of the polyethylene glycol is selectively in bond connection with a free sulfhydryl (-SH) of the protein molecule in neutral and alkaline conditions; the modified polyethylene glycol recombinant human arginase I has a strong in vivo effect and a prolonged vivo half-life period, can inhibit growth of some human hepatoma cells and melanoma cells, particularly the human hepatoma cell resisting against arginase deiminase (ADI).
Owner:BEIJING SL PHARMA
Breeding method for arginase transgenic corn
InactiveCN103045641AIncreased levels of arginaseYield traits such as grain width increaseVector-based foreign material introductionAngiosperms/flowering plantsAgricultural scienceGermplasm
The invention discloses a breeding method for arginase transgenic corn, which comprises the steps of cloning ZmArg genes in the corn, converting an extremely early selfing line of the corn by an agrobacterium mediation method, and creating a high-yield new corn germplasm. With the method, the high-efficiency extraneous ZmArg genes are transplanted into the selfing line of the corn and expressed successfully; the arginase levels in various growth periods of the corn are raised to some extent; and yield traits such as thick corncobs, long niblets and wide niblets are correspondingly improved.
Owner:NORTHEAST AGRICULTURAL UNIVERSITY
Arginase formulations and methods
ActiveUS20120177628A1High degree of homogeneityHigh molecular weightPeptide/protein ingredientsHydrolasesArginasePEGylation
Methods and composition for generation of arginase variants with high serum persistence are provided. For example, in certain aspects methods for purifying pegylated arginase are described. Furthermore, the invention provides stabilized arginase multimers or pharmaceutical composition thereof.
Owner:AERASE
Methods for purifying pegylated arginase
ActiveUS8679479B2High degree of homogeneityHigh molecular weightHydrolasesPeptide/protein ingredientsArginasePEGylation
Owner:AERASE
Method for producing L-ornithine hydrochloride through immobilized enzyme process
InactiveCN101851646AProduction operation safetyHigh purityOn/in organic carrierFermentationOrnithine synthesisL-Ornithine
The invention relates to a preparation method for L-ornithine hydrochloride. The L-ornithine hydrochloride is produced through converting arginase. The method comprises the following technological steps: (1) preparing immobilized enzyme; (2) optimizing conversion conditions; and (3) extracting products and refining. Compared with the prior art, the invention has the advantages that the production cost is low, the production conditions are mild, the impurities in the conversion system are less, the technological steps are simple, the production and the operation are safe, the purity is high, one liter of solution contains 100-130g of L-ornithine hydrochloride, the yield is high, the conversion rate of arginine reaches more than 95 percent and the like.
Owner:湖南天成生化科技有限公司
Method for displaying human arginase1 on surfaces of escherichia coli
InactiveCN105886491AImprove display efficiencyIncrease enzyme activityBacteriaHydrolasesAntigenCompetent cell
The invention provides a method for displaying human arginase1 on surfaces of escherichia coli. The method comprises steps as follows: 1) recombinant plasmids for surface display of human arginase1 are constructed; 2) the recombinant plasmids are converted into escherichia coli competent cells, and genetic engineering strains are obtained; 3) the recombinant strains are subjected to shake-flask culture, and the display efficiency and enzyme activity of human arginase1 are detected; 4) L-Arginine (L-arginine, L-Arg) is efficiently converted by means of the recombinant strains for synthesis of L-Ornithine (L-ornithine, L-Orn). Human arginase1 is effectively displayed on surfaces of escherichia coli cells through improved Type V self-transport protein (Antigen 43), and industrial application of human arginase1 is realized more rapidly. By comparison with an original Type V self-transport protein (Antigen 43) display system, the display efficiency and the enzyme activity of human arginase1 are remarkably improved; by comparison with an existing chitin immobilization method, the synthesis cost is reduced, the technological process is shortened, and the purification procedures are simplified.
Owner:HUBEI UNIV
Medicine composition and method for treating hepatitis with arginase
InactiveCN1745847ALower arginine levelsPeptide/protein ingredientsDigestive systemPharmaceutical drugHepatitis
Owner:BIO CANCER TREATMENT INT
Enzymatic conversion method of L-ornithine
ActiveCN104830922AIncrease costReduce manufacturing costMicroorganism based processesFermentationBiotechnologyOrnithine synthesis
The invention belongs to the field of bio-techniques and particularly relates to an enzymatic conversion method of L-ornithine. The method includes: adding bacterial cells of arginase activity or crude enzyme extract into liquor containing arginine, or crude arginine, or crude arginine salt, serving as substrate preparation enzyme conversion liquid, allowing enzymatic reaction at 25 DEG C to 55 DEG C under pH of 7 to 11, and performing separation by the combination of isoelectric point crystallization and ion exchanging so as to obtain a conversion product, L-ornithine salt. The method has the advantages such that the L-ornithine salt of high added value is synthesized by a substrate enzymatic method with the low-cost L-ornithine liquor, the range of material sources is wide, enzymatic reaction is efficient, operating is convenient, and production cost is low.
Owner:NANJING UNIV
Strain for producing citrulline and method for biologically synthesizing citrulline with same
InactiveCN102433289AEfficient productionSuitable for mass productionBacteriaMicroorganism based processesCitrullineMarket potential
The invention provides a strain for producing citrulline and a method for biologically synthesizing citrulline with the same, belonging to the food biotechnology field. The strain and the method have the following beneficial effects: the invention relates to potential new species kurthiasp.nov. (SK23.003) screened from the soil; kurthiasp.nov. has been collected in the China Center for Type Culture Collection, with collection number being CCTCC NO:M2011467; the strain is taken as the fermentation strain, arginine is taken as the inducer, glucose is taken as the carbon source and yeast cream and peptone are taken as the nitrogen sources to form a fermentation medium; citrulline is prepared through fermentation or is synthesized through transformation by adding a thallus which is produced through fermentation and contains arginase to 5-20% of arginine solution; through detection, the transformation rate can be more than 80%; citrulline produced by the method is safe and reliable, is a functional product with great market potential and is widely applied to such industries as food, cosmetics, medicines and the like; and the method can be used for efficiently producing citrulline and is suitable for large scale production.
Owner:JIANGNAN UNIV
Protection against herbivores
The present invention relates to genes, proteins and methods comprising molecules that alter amino acid levels. In one embodiment, the present invention relates to altering guanidino substrate hydrolysis activities in plants, arthropods and microorganisms using molecules within the arginase family and other molecules that alter an amino acid levels. In ones embodiment, the present invention relates to altering threonine substrate deamination and dehydration activities in plants, arthropods and microorganisms using molecules within the threonine deaminase family and other molecules that alter amino acid levels. In one embodiment, the present invention relates to using genes, proteins and methods comprising arginase or threonine deaminase for altering the pathophysiology of plants, arthropods and microorganisms. In a preferred embodiment, the present invention relates to altering guanidino substrate hydrolysis activity in plants, arthropods, and microorganisms using arginase. In another preferred embodiment, the invention relates to altering threonine substrated deamination and dehydration activity in plants, arthropods, and microorganisms using threonine deaminase. In some embodiments, the invention related to overexpression and increased activity of arginase, threonine deaminase and a proteinase inhibitor.
Owner:BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIV
Preparation method for L-ornithine-alpha-ketoglutarate
InactiveCN102373245AHigh purityIncrease productionOn/in organic carrierFermentationTransformation efficiencyL-Ornithine
The present invention relates to a preparation method for L-ornithine-alpha-ketoglutarate. The L-ornithine-alpha-ketoglutarate is produced by arginase transformation. The preparation method comprises the following steps: (1) preparation of immobilized enzyme; (2) optimization of transformation conditions; (3) product extraction and refining process. Compared to the prior art, the preparation method of the present invention has the following advantages that: the preparation method of the present invention has characteristics of low production cost, mild production conditions, less impurities in the transformation system, simple process steps, safe production operation and high purity; qualified products meeting the light transmission requirements can be synthesized; each liter of the reaction solution contains 300-320 g of the L-ornithine-alpha-ketoglutarate, and the transformation efficiency of the alpha-ketoglutaric acid is more than 90%; the preparation method further has other advantages.
Owner:湖南天成生化科技有限公司
Strain for producing ornithine and method for biologically synthesizing ornithine with same
InactiveCN102433288AEfficient productionSuitable for mass productionBacteriaMicroorganism based processesNitrogen sourceArginase
Owner:JIANGNAN UNIV
Method for immobilizing human source arginase-1 through surface display
ActiveCN105713888AImmobilizationImprove display efficiencyHydrolasesVector-based foreign material introductionSurface displayL-Ornithine
The invention discloses a method for immobilizing human source arginase-1 through surface display. The method comprises the steps of adding signal peptide and charged polypeptide to the amino terminal of a protein cleavage variant (InaK-N) formed on an ice core, fusing human source arginase-1 into the carboxyl terminal, and designing an HA label at the carboxyl terminal; constructing various recombinant plasmids to convert competent escherichia coli cells, so that different genetic engineering strains are obtained; conducting shake-flask culture on the strains; detecting the display efficiency and enzyme activity of human source arginase-1; selecting the strain with the highest enzyme activity for mass culture, conducting efficient L-arginine conversion, and synthesizing L-ornithine. Human source arginase-1 fused in the protein cleavage variant formed on the ice core is effectively displayed on the surface of an escherichia coli cell, so that human source arginase-1 is immobilized. Compared with an original ice core protein display system, the method has the advantage that the display efficiency and enzyme activity of human source arginase-1 are improved remarkably. Compared with a chitin immobilizing method, the method has the advantages that cost is reduced, process is shortened, and purification steps are simplified.
Owner:HUBEI UNIV
Combination therapy with glutaminase inhibitors and immuno-oncology agents
InactiveUS20170095473A1Chronic infectionAntibacterial agentsOrganic active ingredientsDiseaseImmunooncology
The invention relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases with a combination of a glutaminase inhibitor and an immuno-oncology therapeutic agent, such as an inhibitor of arginase, CTLA-4, indoleamine 2,3-dioxygenase, and / or PD-1 / PD-L1.
Owner:CALITHERA BIOSCIENCES INC
Use of pegylated recombinant human arginase for treatment of leukemia
Owner:BIO CANCER TREATMENT INT
Recombinant human arginase fusion protein and application thereof
InactiveCN101781369AAchieve enrichmentAvoid damagePeptide/protein ingredientsDigestive systemTherapeutic effectGenetic engineering
The invention belongs to the field of gene engineering, which relates to a recombinant human arginase fusion protein and application thereof. The recombinant human arginase fusion protein is a recombinant human arginase fusing any one polypeptide with an amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. The fusion protein can effectively achieve the enrichment of drug in the tumor site and prevent homeostatic mechanism of amino acid to a certain degree so as to obtain good therapeutic effect.
Owner:JIANGSU SIMCERE PHARMACEUTICAL R & D CO LTD
Compositions and methods for inhibiting arginase activity
ActiveUS20170121352A1Improve throughputLimit deliveryBoron compound active ingredientsAntibody ingredientsArginaseMedicinal chemistry
Owner:PRECISION PHARM INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com